Supporting the

Neuroendocrine Cancer Community

Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel in gastrointestinal and pancreatic neuroendocrine tumours

Jul 24, 2013

Somatuline Autogel extends progression free survival in gastrointestinal and pancreatic neuroendocrine tumours (GEP-NETs), according to early results from the CLARINET study (Controlled study of Lanreotide Antiproliferative Response in NET).

“CLARINET is the first prospective large scale placebo-controlled study inclusive of gastrointestinal and pancreatic NETs which provides clear evidence that Somatuline Autogel 120mg delays tumour progression or death, states lead investigator Professor Martyn Caplin (London) in a press release announcing results ahead of more comprehensive details to be presented at the 2013 annual meeting of the European Society of Medical Oncology in September.

The primary endpoint of the 204 patient CLARINET study, which was conducted in collaboration with UKI NETS and ENETS, is time to disease progression assessed by CT scan at intervals up to 96 weeks, or death. According to this early statement by IPSEN the therapy achieved statistically significant results against placebo with a safety profile consistent with that of prior trials with Somatuline.

(Reuters, 11 July 2013)